Trial Profile

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacituzumab Tirumotecan (Primary) ; Dexamethasone; Diphenhydramine; Doxorubicin; Paclitaxel; Paracetamol
Indications Carcinoma; Endometrial cancer; Sarcoma
Focus Registrational; Therapeutic Use
Acronyms TroFuse-005
Sponsors Merck Sharp & Dohme

05 Jan 2024 According to Merck media release, the trial have been initiated and patients are now enrolling.
12 Dec 2023 Status changed from not yet recruiting to recruiting.
06 Dec 2023 Phase is changed from phase 2/3 to phase 3.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com